Alternatives to the Use of Fetal Bovine Serum: Human Platelet Lysates as a Serum Substitute in Cell Culture Media

Caroline Rauch 1, Elisabeth Feifel 1, Eva-Maria Amann 2, Hans Peter Spötl 2, Harald Schennach 2, Walter Pfaller 1, and Gerhard Gstraunthaler 1

1 Division of Physiology, Innsbruck Medical University, Innsbruck, Austria; 2 Central Institute of Blood Transfusion and Immunology, University Hospital, Innsbruck, Austria

Summary
The search for alternatives to the use of fetal bovine serum (FBS) in cell and tissue culture media has become a major goal in terms of the 3R principles in order to reduce or to avoid harvesting of FBS from bovine fetuses, and, in terms of Good Manufacturing Practice (GMP), to ensure safe and animal product-free conditions for biomedical tissue engineering and (adult) stem cell therapy, respectively. In the present study, we investigated the feasibility of using platelet lysates (PL) as a substitute for FBS, based on the fact that most of the potent mitogenic factors present in serum are derived from activated thrombocytes. Platelet lysates were obtained from outdated human donor platelet concentrates. Methods were established to activate human donor platelets in order to achieve a maximum yield of platelet α-granule growth factors. Platelet lysates were successfully introduced to grow and maintain anchorage-dependent and -independent human and animal cell lines. For cell culture experiments, cells were either grown in culture media supplemented with 10% FBS, 5% PL, or under serum-free conditions. Growth experiments, viability assays, and platelet lysate-induced activation of ERK1/2 mitogen-activated protein kinase revealed platelet lysates as a valuable alternative to FBS in cell culture media.

Keywords: cell culture media, fetal bovine serum, serum-free cell culture, platelet lysates, non-animal alternatives

1 Introduction

Propagation of human and animal cells in vitro requires adequate culture conditions and culture media. The culture medium has to supply all essential nutrients for cell metabolism, growth and proliferation. Basal media are frequently supplemented with animal serum, mostly fetal bovine serum (FBS), which promotes cell growth and proliferation (Gstraunthaler, 2003; Lindl und Gstraunthaler, 2008). Animal serum is an extremely complex mixture of a large number of constituents, including low and high molecular weight biomolecules with different physiologically balanced growth-promoting and growth-inhibiting activities. The major functions of serum in culture media are to provide hormonal factors stimulating cell growth and proliferation, to promote differentiated functions, and to provide transport proteins, minerals, trace elements, lipids, attachment and spreading factors, and stabilizing and detoxifying factors needed for maintaining pH or to inhibit proteases either directly, such as α-antitrypsin, or indirectly, by acting as an unspecific sink for proteases and other (toxic) molecules. FBS is superior to serum from adult animals because of its low gamma-globulin content, as a high content of antibodies may inhibit growth and proliferation.

Recently, major concerns were raised about the welfare of donor fetuses during harvesting of fetal blood (Brunner et al., 2010; van der Valk et al., 2004, 2010). Bovine fetuses from which blood is drawn for FBS production are obtained from pregnant cows sent to slaughter. When a pregnant cow is discovered at the slaughterline, the fetus is separated at the abattoir, and fetal blood is collected under aseptic conditions by puncturing the beating heart of the unanesthetized fetus using large diameter needles. Thus, fetal blood collection involves significant manipulation of the fetus (Jochems et al., 2002). The use of in vitro human cell culture for tissue engineering, (adult) stem cell technology, and cell-based therapy has gained in importance during the last decade (Leist et al., 2008; Park and Eve, 2009; Taupin, 2007). Because of the undefined composition of FBS, the risk of contaminations, animal welfare concerns regarding its harvest and production, along with the problems of limited availability and the cost factor, the
switch to serum-free alternatives is promoted by regulatory authorities, industry, and the research community in general (Falkner et al., 2006; Brunner et al., 2010; van der Valk et al., 2010). Examples for the limited usage of FBS are the field of multipotent mesenchymal stromal cells (MSCs) (Lange et al., 2007) and human embryonic stem cells (hESC). Concerns were raised that the incorporation of the nonhuman N-glycolneuraminic acid (Neu5Gc), present in animal serum, excludes FBS from application in human ES for cellular therapy (Martin et al., 2005; Taupin, 2006).

Other laboratories have already suggested that platelet lysates are a valuable, non-xenogenic alternative to FBS in cell culture (Bernardo et al., 2007; Doucet et al., 2005; Johansson et al., 2003). Physiologically, activated platelets are known to deliver a broad spectrum of growth factors and other active molecules by exocytosis at the site of injury. The growth factors released from α-granules include platelet-derived growth factor (PDGF), epithelial growth factor (EGF), vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), and transforming growth factor β1 (TGF-β1) (King and Reed, 2002; Maguire and Fitzgerald, 2003; Reed et al., 2000; Rendu and Brohard-Bohn, 2001).

However, almost all lysates used so far contained high volumes of donor serum, i.e. potential allograft material (Abrams, 2005; Bieback et al., 2009; Spaepen et al., 2009). In the present study it was investigated whether separation of platelets from donor serum by washing in saline before their in vitro processing would provide lysates that promote cell growth and can be used as an alternative to FBS. As cell culture models continuous human and animal cell lines, grown as monolayers or in suspension, were used (Gstraunthaler, 1988).

2 Materials and methods

Preparation of human platelet lysates

Outdated human donor platelets obtained by apheresis methods (Amicus™, Fenwal, Lake Zurich, IL, USA; Trimas™, CaridianBCT, Lakewood, CO, USA) were provided by the blood bank of the Innsbruck Medical University Hospital. Platelet donor bags (one bag per donor) were each processed separately. Platelet concentrates, containing at least 2 x 10¹¹ donor platelets, were transferred under sterile conditions into 250 ml centrifugation cups and centrifuged at 6,000 x g for 20 min in order to remove platelet additive solution (PAS) (Shanwell et al., 2000). The supernatant was aspirated and the platelets were washed with 0.9% NaCl. Platelets were resuspended in 15 ml 0.9% NaCl with a final cell count of ~1.5 x 10¹⁰ platelets/ml. The suspension was stored at -20°C before lysate preparation by three freeze/thawing cycles. Aliquots of the platelet lysate were again stored at -20°C for use within 4 weeks. Before addition to serum-free culture media, aliquots were thawed and spun at 8,000 x g for 10 min and supernatants were taken.

To identify the most efficient platelet activation method in order to achieve a maximum yield of growth factors, different physiological/biochemical or mechanical methods of in vitro platelet activation were tested (Burnouf et al., 2008; Gstraunthaler et al., 2000; Kamath et al., 2001; Reed et al., 2000; Rendu and Brohard-Bohn, 2001). Of the methods tested (coagulation with CaCl₂, activation with ADP, fibrillar collagen type I, thrombin, thrombin receptor activating peptide, or zeolite), freeze-thawing of platelet suspension turned out to be the most effective procedure (Barano and Hammond, 1985). The method induces platelet disruption by hypo-osmotic shock and three repeated freezing/thawing cycles at -20°C.

Counting of platelets

Determination of platelet counts was performed by using the CASY® Technology Model TT (innovatis AG, Bielefeld, Germany). Platelets were diluted in 0.9% NaCl for measurement with a 60 µm diameter measuring capillary.

Cell culture

For tissue culture experiments mainly renal epithelial cells, particularly immortal LLC-PK₁, LLC-PK₁-FBPass, MDCK, OK, and HK-2 cells were used (Gstraunthaler, 1988). Furthermore, the human leukemia cell lines Raji and THP-1 were used as models for suspension cultures. Cultures were incubated at 37°C with 5% CO₂. Routinely, cultures were fed three times a week. Confluent monolayers were subcultured with 0.25% trypsin and 0.02% EDTA in Ca²⁺- and Mg²⁺-free buffered saline. Experimental cultures were grown in 10 cm plastic tissue culture dishes until confluent monolayers were achieved using 7 ml culture medium.

Cell culture media were prepared from DMEM (Dulbecco’s Modified Eagle’s Medium) base (Cat. No. D-5030, Sigma-Aldrich, Vienna, Austria) supplemented with 5.5 mM D-glucose, 2 mM L-glutamine, 26.2 mM NaHCO₃ and 17.8 mM NaCl to correct for medium osmolarity (Gstraunthaler et al., 2000), 10% FBS (Biochrom, Berlin, Germany), 1 mM sodium pyruvate, 0.011 g/l phenol red and 100 U/ml penicillin and 100 µg/ml streptomycin. Suspension cultures were grown in RPMI-1640 medium supplemented with 10% FBS and antibiotics. For culturing cells with platelet lysates, FBS was replaced by 5% PL. Serum-free cultures were without addition of either FBS or PL. All media additives were of tissue culture grade and were obtained from Sigma-Aldrich. Tissue culture plastic ware and culture dishes were from Greiner (Greiner Bio-One, Kremsmünster, Austria).

Cell counting

Cell densities of epithelial cultures were determined as cell counts per area as described elsewhere (Pfaller et al., 1990; Lindl und Gstraunthaler, 2008).

Cell extraction

For Western blotting, cells were harvested in freshly prepared ice-cold RIPA-buffer (Feifel et al., 2002). The lysate was centrifuged at 10,000 x g and 4°C for 5 min. The supernatant was transferred into new tubes and stored at -20°C. The phosphatase inhibitors sodium orthovanadate and β-glycerophosphate were added to maintain the proteins in the phosphorylated state. The protease-inhibitor cocktail (Cat. No. P8340, Sigma-Aldrich) was added to prevent proteolysis.
Viability Assay

The WST-8 solution (Cat.No. 96992, Sigma-Aldrich) was added to cells grown in 6-well culture plates to a final concentration of 10% and incubated for 2 h at 37°C. WST-8 is reduced by dehydrogenases in cells to give a yellow-colored product (formazan), correlating to the number of metabolically active cells in the culture. Formazan formation was measured at 450 nm.

Scanning Electron Microscopy

Control donor platelets and platelets after one cycle of freeze/thawing were fixed in glutaraldehyde before filtration and subsequent preparation for scanning electron microscopy. In brief, control and activated platelet suspensions were pipetted into 0.1 M sodium cacodylate/2.5% glutaraldehyde, pH 7.4 in a 15 ml test tube and incubated for 30 min on ice. Afterwards, platelets were sucked onto Millipore filters (pore size: 0.2 and 2.0 µm) that were mounted on a glass screen in a filtration unit. Dried filters were transferred to 6-well culture plates and covered with cacodylate/glutaraldehyde for 30 min. Thereafter, filters were washed with PBS, post-fixed with OsO4 for 30 min and washed again with PBS. Filters were then dehydrated with 30%, 50%, 75%, and 95% methanol, each for 10 min, and 3 times with 100% methanol at RT. After critical point drying, filters were sputtered with gold-palladium for scanning electron microscopy. SEM was carried out on a Jeol SM25 at 15 kV.

3 Results

3.1 Effects of treatment on platelets

Morphological changes of platelets

The morphological changes of human thrombocytes by freeze/thawing were visualized by scanning electron microscopy. Representative photographs are displayed in Figure 1. Resting plate-
3.2 Growth factor content of platelet lysates

Concentrations of different growth factors in platelet lysates were quantified via enzyme-linked immunosorbent assay (ELISA) in 11 batches of platelet lysates (Kamath et al., 2001; Reed et al., 2000). Tab. 1: Growth factor contents in platelet lysates of different donor batches

Lysates were prepared from platelet concentrates containing ~1.5 x 10^10 platelets/ml. For comparison, two human serum samples were analysed. n.d., not determined.

<table>
<thead>
<tr>
<th>Lysate Samples</th>
<th>EGF [ng/ml]</th>
<th>PDGF-AB [ng/ml]</th>
<th>TGF-β1 [ng/ml]</th>
<th>HGF [ng/ml]</th>
<th>IGF-1 [ng/ml]</th>
<th>bFGF [ng/ml]</th>
<th>VEGF [ng/ml]</th>
</tr>
</thead>
<tbody>
<tr>
<td># 56</td>
<td>11.63</td>
<td>57.28</td>
<td>1,179.7</td>
<td>1.17</td>
<td>12.81</td>
<td>0.96</td>
<td>8.46</td>
</tr>
<tr>
<td># 69</td>
<td>15.34</td>
<td>76.48</td>
<td>533.2</td>
<td>1.38</td>
<td>16.70</td>
<td>1.04</td>
<td>3.47</td>
</tr>
<tr>
<td># 70</td>
<td>20.55</td>
<td>53.60</td>
<td>1,462.6</td>
<td>1.46</td>
<td>8.90</td>
<td>1.05</td>
<td>10.63</td>
</tr>
<tr>
<td># 71</td>
<td>13.45</td>
<td>58.26</td>
<td>503.7</td>
<td>2.48</td>
<td>16.13</td>
<td>0.90</td>
<td>19.65</td>
</tr>
<tr>
<td># 72</td>
<td>16.69</td>
<td>46.34</td>
<td>1,272.5</td>
<td>0.68</td>
<td>9.32</td>
<td>0.81</td>
<td>5.17</td>
</tr>
<tr>
<td># 73</td>
<td>14.27</td>
<td>51.88</td>
<td>1,084.3</td>
<td>1.22</td>
<td>16.66</td>
<td>0.98</td>
<td>19.99</td>
</tr>
<tr>
<td># 108</td>
<td>13.44</td>
<td>89.26</td>
<td>518.1</td>
<td>1.65</td>
<td>25.89</td>
<td>1.33</td>
<td>1.27</td>
</tr>
<tr>
<td># 134</td>
<td>16.40</td>
<td>96.08</td>
<td>669.2</td>
<td>1.39</td>
<td>n.d.</td>
<td>2.55</td>
<td>1.36</td>
</tr>
<tr>
<td># 162</td>
<td>22.58</td>
<td>118.79</td>
<td>692.9</td>
<td>2.57</td>
<td>n.d.</td>
<td>2.97</td>
<td>1.12</td>
</tr>
<tr>
<td># 173</td>
<td>37.11</td>
<td>162.75</td>
<td>350.1</td>
<td>1.78</td>
<td>n.d.</td>
<td>4.52</td>
<td>1.01</td>
</tr>
<tr>
<td># 194</td>
<td>20.27</td>
<td>115.32</td>
<td>191.2</td>
<td>1.28</td>
<td>n.d.</td>
<td>4.41</td>
<td>5.32</td>
</tr>
<tr>
<td>Mean</td>
<td>18.34</td>
<td>84.19</td>
<td>768.9</td>
<td>1.55</td>
<td>15.20</td>
<td>1.96</td>
<td>7.04</td>
</tr>
<tr>
<td>±SD</td>
<td>±6.76</td>
<td>±34.86</td>
<td>±395.0</td>
<td>±0.53</td>
<td>±5.34</td>
<td>±1.36</td>
<td>±6.72</td>
</tr>
<tr>
<td>Human</td>
<td>1.52</td>
<td>4.64</td>
<td>46.87</td>
<td>0.80</td>
<td>75.96</td>
<td>0.0019</td>
<td>0.063</td>
</tr>
<tr>
<td>Serum</td>
<td>0.02</td>
<td>5.20</td>
<td>33.85</td>
<td>0.62</td>
<td>83.98</td>
<td>0.018</td>
<td>n.d.</td>
</tr>
</tbody>
</table>

Mean ± SD for each factor, with human and serum data also included. The data show a consistent range of growth factor concentrations across different lysate samples. P-selectin release after treatment

In order to estimate the extent of α-granule release, the amount of P-selectin in supernatants and platelet lysates was determined by Western blotting.

As shown in Figure 2, platelet lysates showed clear bands of P-selectin, while supernatants and wash fractions were negative. The data indicate that centrifugation and careful washing steps do not activate the platelets, and that freeze/thawing is sufficient for maximal release of α-granule growth factors and P-selectin, respectively.

3.2 Growth factor content of platelet lysates

Concentration of different growth factors in platelet lysates

Concentrations of α-granule growth factors bFGF, EGF, HGF, IGF-I, PDGF-AB, TGF-β1 and VEGF were quantified via enzyme-linked immunosorbent assay (ELISA) in 11 batches of platelet lysates (Kamath et al., 2001; Reed et al., 2000). Growth
factor concentrations in lysate preparations are listed in Tab. 1. For comparison the levels of these factors determined in two unrelated human serum samples are given.

Platelet-derived growth factor (PDGF), a strong mitogen, is a major constituent of α-granules. Concentrations found in platelet lysates are in the range of 50-100 ng/ml (Tab. 1), indicating a 10- to 20-fold enrichment compared to normal serum levels. Epidermal growth factor (EGF), which is present in a number of serum-free culture media formulations in recommended concentrations of 1-100 ng/ml, is also a strong mitogen (Barnes and Sato, 1980; Gstraunthaler, 2003). Mean EGF contents in platelet lysates are in the range of ~20 ng/ml compared to ~1 ng/ml in human serum.

The different batches show concentration differences. These differences are likely attributable to individual donor factors, such as age and sex. Overall, the platelet lysates contained higher levels of α-granule factors PDGF-AB, EGF, bFGF, HGF, TGF-β1 and VEGF than the serum samples, whereas the level of the liver-derived serum marker IGF-1 was higher in the serum sample. Platelet lysates also showed a lower protein content than human serum, which is consistent with the removal of immunoglobulins and albumin in the washing procedure.

Based on these results, the following quality criteria for platelet lysates could be defined: high contents of PDGF-AB, VEGF, EGF, bFGF, and TGF-β1, and low IGF-1 content and low protein content (~10 mg/ml).

Growth factor stability during storage of platelet lysates
To test the stability of platelet lysates during long-term storage, lysates were stored at -20°C for five months. Every month, the content of EGF as a representative lysate growth factor marker was determined. Results show a strong stability of EGF in platelet lysates over the test period under this storage condition (Fig. 3).

Growth-promoting effects of platelet lysates on cell lines
For investigation of the growth-promoting effect of platelet lysates, cell culture experiments with a variety of human and animal cell lines were performed. Different concentrations of standardized platelet lysates (1%, 5% and 10% v/v) were added as serum replacement to serum-free basal culture media. Results from pilot experiments revealed that addition of 5% was sufficient to promote cell proliferation (data not shown). The cells were cultured for up to 28 days, phase contrast micrographs were taken at day 3, 7, 14, and 28.

The results after 14 days with LLC-PK1 and LLC-PK1-FBPase+ porcine kidney cells, MDCK canine kidney cells, HK-2 human kidney cells, and OK opossum kidney cells (Gstraunthaler, 1988) are depicted in Figure 4. As can be seen, 5% platelet lysate supplementation fully supported growth and proliferation of the renal epithelial cell lines comparable to cultures with 10% FBS.

Raji cells (human lymphoblastoid cell line) and THP-1 cells (human acute monocytic leukemia cell line) were used as models for suspension-grown cultures (Fig. 5). 5% Platelet lysate also fully supported the growth of the human suspension cell lines.

Furthermore, primary cultures of human chondrocytes, isolated from cartilage tissue in a tissue engineering laboratory, proliferated in media with 10% platelet lysates in human collagen-coated culture dishes. Human cornea epithelia were also successfully maintained in platelet lysate-supplemented media (data not shown).

For investigation whether cell attachment and growth can be enhanced by collagen-coating, we used collagen-coated cell dish-

![Fig. 3: Growth factor stability of EGF in platelet lysates stored at -20°C for five months](image-url)

Values are expressed as means ±SD of four lysate samples.
Fig. 4: Cell growth experiments using animal and human renal epithelial cell lines (LLC-PK₁ pig kidney cell line, LLC-PK₁-F⁺ strain, MDCK Madin-Darby canine kidney cell line, HK-2 human kidney cell line, OK opossum kidney cells) Cells were grown on DMEM with either 10% FBS, without any supplementation (serum-free, SF) or with the addition of 5% platelet lysate (PL). Phase contrast micrographs were taken after 14 days in culture. Magnification 20 x.
Growth curves of LLC-PK1 and MDCK cells to quantify the cell growth experiments, representative growth curves for LLC-PK1 and WST-8 proliferation assay for MDCK cultures, respectively (Lindl and Gstraunthaler, 2008). The results in Figure 6 clearly revealed that in both methods the growth-promoting effect of 5% platelet lysate is almost identical to that of 10% FBS.

3.3 Cell growth promotion by platelet lysates

Growth curves of LLC-PK1 and MDCK cells

To quantify the cell growth experiments, representative growth curves for LLC-PK1 and MDCK cultures were determined by in situ-cell counting for LLC-PK1 and WST-8 proliferation assay for MDCK cultures, respectively (Lindl and Gstraunthaler, 2008). The results in Figure 6 clearly revealed that in both methods the growth-promoting effect of 5% platelet lysate is almost identical to that of 10% FBS.
Stimulation of ERK1/2 MAP kinases

In order to visualize the mitogenic effect of growth factors in platelet lysates, phospho-specific ERK Western blots using LLC-PK1 cells were performed. For this blotting technique, phospho-specific antibodies against ERK1 and ERK2 were used. ERK1 and ERK2 are members of the MAPK family, which belong to a specific transcriptional activation cascade involved in many cell regulating processes. ERK1/2 are activated by specific phosphorylation that initiates the transcription of genes leading to cell growth and proliferation (Feifel et al., 2002; Schramek, 2002).

The Western blots presented in Figure 7 show the induction of ERK1/2 phosphorylation in FBS- or platelet lysate-stimulated LLC-PK1 cells. LLC-PK1 cultures were serum-deprived for 24 h and then stimulated by the addition of 10% FBS, 5% platelet lysate or serum-free medium without any supplementation with growth factors or hormones. The bands show distinct phosphorylation of ERK1 and ERK2. Phosphorylation, and thus ERK activation starts about two minutes after stimulation, with a peak after ten minutes and a decrease to basal values after 3 h. Platelet lysate-treated cells show a slightly higher stimulation after 5 min compared to FBS. Addition of serum-free medium served as a control. Equal protein loading was assessed by staining with a pan ERK2 antibody (lower panels).

4 Discussion

The 3Rs are guiding principles for the use of animals in research and testing, first described by Russell and Burch more than 50 years ago (Balls, 2010; Balls et al., 1995). Their intention was to reduce pain and fear of experimental animals defined by the 3Rs concept (Refine, Reduce, and Replace). Refinement means any decrease in the incidence or severity of inhumane procedures. Reduction means the reduction in the numbers of animals used to obtain information of a given amount and precision. Replacement means the substitution of any experimental animals by in vitro and/or in silico methods (Fletcher et al., 2011; Mahadevan et al., 2011).

The search for alternatives to replace fetal bovine serum (FBS) has become a major goal in the field of cell and tissue
culture. The efforts to develop a substitute for FBS are primarily based on two intentions. On the one hand, harvest and production of FBS is ethically problematic, and thus a replacement is needed (Brunner et al., 2010; Jochems et al., 2002; van der Valk et al., 2004). On the other hand, the rapidly expanding fields of *in vitro* cell and tissue culture, biomedical tissue engineering, and (adult) stem-cell therapy require defined, safe, and animal component-free culture conditions (Atala, 2007; van der Valk et al., 2010). In case of the scientific aspect the substitution of sera would lead to a better quality and reproducibility of experimental data as suggested by Good Cell Culture Practice (Balls et al., 2006; Coecke et al., 2005; Gstraunthaler, 2006, 2010; Hartung et al., 2002). Serum or FBS is known to be a chemically ill-defined supplement, bearing qualitative and quantitative variations that exhibit a possible source of microbial contamination with fungi, bacteria, viruses, mycoplasma, and prions (Brunner et al., 2010; Gstraunthaler, 2003; van der Valk et al., 2010).

More than 30 years ago (Hayashi and Sato, 1976) researchers started efforts to find alternatives to animal serum (Brunner et al., 2010; Gstraunthaler, 2003; Lindl und Gstraunthaler, 2008). Since then a whole range of substitutes have become commercially available or are still under investigation, including chemically-defined media substitutes, tissue extracts (e.g., pituitary extracts), ocular fluid (Filipic et al., 2002), bovine milk fractions or bovine colostrum (Belford et al., 1995), plant extracts (vegetal serum) (Pazos et al., 2004), and platelet lysates (Johansson et al., 2003).

Serum, rather than plasma, promotes the growth and proliferation of cultured cells (Gospodarowicz and Ill, 1980). In the past, much effort was spent to identify the factors in serum that stimulate cell growth *in vitro*. An important step forward in the search for serum growth factors has been the finding that the most potent mitogenic factors present in serum are derived from activated thrombocytes (Balk et al., 1981; Gospodarowicz and Ill, 1980).

Platelets are known to be a rich source of growth factors (Marx et al., 1998; Weibrich et al., 2002; Anitura et al., 2004), thus suggesting platelet lysates as a valuable animal serum substitute. Platelet lysates were tested on mesenchymal stem cells (MSCs), concluding that the lysates were more efficient in terms of costs and proliferation rate than using exogenous recombinant growth factors and retained their immunosuppressive (Doucet et al., 2005) as well as their differentiation capability (Lange et al., 2007).

Donor platelets have a shelf life of five days for therapeutic applications, but they retain all growth factors for at least three weeks (Chan et al., 2005). Outdated donor platelets obtained by apheresis were separated from the plasma or platelet additive solution (PAS) (Shanwell et al., 2003) by centrifugation and gentle resuspension in physiological saline. The counting of platelets by the CASY® Cell Counter revealed a marginal loss of platelets during the preparation procedure. The platelet suspension yielded an average platelet count of $1.5 \times 10^{10}/\text{ml}$.

Pilot experiments established freeze/thawing as the method of choice for enriching α-granule derived components. Besides being the most economic method, a further advantage of this physical method is that the platelet lysates do not contain traces of biochemical activators.

The morphological status of platelets was visualized by scanning electron microscopy (SEM), and platelet degranulation was determined by specific P-selectin release (Fig. 1, 2). P-selectin, also known as CD62P or PADGEM is a transmembrane protein of the α-granule that is released together with the granule content into the supernatant (McEver, 1995; Blann and Lip, 1997).

The lysates obtained by freeze/thawing showed high concentrations of the α-granule derived growth factors EGF, bFGF, HGF, PDGF-AB, TGF-β1, and VEGF. As expected, the content of liver-derived IGF-1 was lower in the lysates than in human serum samples. The low protein concentration of about 10 mg/ml suggests a low concentration of extraneous material, thus reducing the risk of causing immunological reactions.

Platelet-derived growth factor concentrations have also been investigated by several other laboratories (Christgau et al., 2006; Cognassse et al., 2006; Doucet et al., 2005; Frechette et al., 2005; Gruber et al., 2002; Kaps et al., 2002; Lacoste et al., 2003; Ogino et al., 2006; Schallmoser et al., 2007; Shen et al., 2006; Weibrich et al., 2002; Zimmermann et al., 2003). The results of these analyses are not comparable with our results, because of different preparation methods: All except El Backly et al. and Gruber et al. (El Backly et al., 2011; Gruber et al., 2002) stored platelets in serum, which also contains growth factors, and/or in platelet additive solution.

We further assessed the stability of the growth factors in the platelet supernatant during long-term storage. EGF was chosen as a marker as it is commonly used in cell culture media. Results showed that EGF is stable at -20°C for at least five months (Fig. 3).
In order to biochemically determine the proliferative potential of platelet lysates, the stimulation of extracellular signal-regulated MAP kinase (ERK1/2) by platelet lysates was determined. ERK1/2, activated by extracellular stimuli such as growth factors or FBS, are part of the MAPK (mitogen-activated protein kinase) signaling network that regulates growth, proliferation, differentiation, and survival of almost all cells (Treisman, 1996; Chang and Karin, 2001; Pearson et al., 2001) (Fig. 8). Addition of 5% platelet lysates to serum-starved, quiescent LLC-PK1 cells induced phosphorylation, and thus activation, of ERK1/2 within minutes. The activation potential of platelet lysates was comparable with that of FBS (Figure 7). In recent functional studies, LLC-PK1 and MDCK epithelia cultured in the presence of platelet lysates generated a transepithelial electrical resistance (TEER) comparable to FBS (manuscript in preparation). TEER is a sensitive indicator for epithelial differentiation, assembly of cell-cell junctional complexes, and vectorial transepithelial solute transport across cultured epithelial layers (Graunthaler, 1988).

Results from our experiments indicate a high potential for platelet lysates as a growth-promoting culture media substitute for a multitude of cell lines. Moreover, the application of platelet lysate would minimize the risk of microbial contaminations (Kuznetsov et al., 2000), reduce immunological reactions (Bartholomew et al., 2002), and be more economical than FBS or recombinant growth factors (Doucet et al., 2005).

Aside from use as a universal serum replacement, platelet lysate could also serve as a substitute for autologous human serum in tissue engineering and biomedical cell therapy (Klimanskaya et al., 2008; Minuth et al., 1998; Stock and Vacanti, 2001). Tissue engineering requires authorized GMP (Good Manufacturing Practice) protocols and autologous culture conditions for the cultivation and expansion of human donor cells (Halme and Kessler, 2006; McDevitt and Palecek, 2008). In order to avoid additional stress for patients by extracting a 400 ml unit of blood for autologous serum production, this could be overcome with the use of platelet apheresis and subsequent platelet lysate production.

In case of platelet transfusion therapy, allogenic platelet concentrates from voluntary donors with blood groups and Rhesus factors identical with the recipients are applied. Thus, also for cultivation and expansion of donor cells, it could be feasible to use allogenic platelet lysate with matching blood group and Rhesus factor (Kaufman, 2009; Shehata et al., 2009; Stroncek and Rebulla, 2007). In this context, the collaboration with a tissue engineering laboratory showed that our platelet concentrates could support the growth of human chondrocytes. Also, human corneal epithelia were successfully maintained in platelet lysate-supplemented media (data not shown).

ESAC, the ECVAM Scientific Advisory Committee, recently endorsed a statement that strongly recommends – whenever possible – the use of non-animal alternatives to FBS in new in vitro test methods: “For methods forwarded to ECVAM for validation/prevalidation where this is not fulfilled, a justification for future use must be provided, including measures taken to seek non-animal alternatives to FBS” (ESAC, 2008).

Thus, platelet lysates can serve as a full “Replacement” in terms of the 3Rs and as a promising substitute for FBS in all in vitro methodologies, like cell and tissue culture, in vitro toxicity studies, prevalidation and validation, tissue engineering, and cell therapy (Leist et al., 2008).

References


Mahadevan, B., Snyder, R. D., Waters, M. D., et al. (2011). Ge-


**Acknowledgements**

The authors thank Mrs. Edna Nemati for the superb scanning electron microscopy work. This study was generously supported by the Pollux Private Foundation.

**Correspondence to**

Gerhard Gstraunthaler, PhD
Innsbruck Medical University
Division of Physiology
Fritz-Pregl-Strasse 3
6020 Innsbruck
Austria
http://physiologie.i-med.ac.at
e-mail: gerhard.gstraunthaler@i-med.ac.at